Solvay took a hard look at its experimental obesity drug and decided that the regulatory hurdles it faces are simply too high. The data for SLV319--in Phase II--"confirmed its clinical activity and its efficacy," according to the company. But the developer opted to shelve its work on the program nevertheless. Release | Report